May 23, 2018
BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa
BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa NEWS PROVIDED BY BERG May 23, 2018, 07:34 ET BOSTON, May 23, 2018 /PRNewswire/ — BERG, LLC, a Boston-based biopharmaceutical company that merges...